Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).

@article{Kraus2018SynovialAS,
  title={Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).},
  author={Virginia B. Kraus and Philip G Conaghan and H A Aazami and Purvi Mehra and Alan J. Kivitz and Joelle Lufkin and J Hauben and James R. Johnson and Neil Bodick},
  journal={Osteoarthritis and cartilage},
  year={2018},
  volume={26 1},
  pages={
          34-42
        }
}
OBJECTIVE Intra-articular (IA) corticosteroids relieve osteoarthritis (OA) pain, but rapid absorption into systemic circulation may limit efficacy and produce untoward effects. We compared the pharmacokinetics (PK) of IA triamcinolone acetonide (TA) delivered as an extended-release, microsphere-based formulation (FX006) vs a crystalline suspension (TAcs) in knee OA patients. METHOD This Phase 2 open-label study sequentially enrolled 81 patients who received a single IA injection of FX006 (5… CONTINUE READING